KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Share-based Compensation: 2015-2025

Historic Share-based Compensation for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $140.8 million.

  • BeOne Medicines' Share-based Compensation rose 22.77% to $140.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.7 million, marking a year-over-year increase of 15.88%. This contributed to the annual value of $441.6 million for FY2024, which is 20.13% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Share-based Compensation is $140.8 million, which was down 6.63% from $150.8 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Share-based Compensation registered a high of $150.8 million during Q2 2025, and its lowest value of $45.8 million during Q1 2021.
  • For the 3-year period, BeOne Medicines' Share-based Compensation averaged around $108.8 million, with its median value being $103.4 million (2023).
  • Data for BeOne Medicines' Share-based Compensation shows a peak YoY skyrocketed of 43.03% (in 2022) over the last 5 years.
  • BeOne Medicines' Share-based Compensation (Quarterly) stood at $63.0 million in 2021, then grew by 23.99% to $78.1 million in 2022, then climbed by 18.94% to $92.9 million in 2023, then rose by 15.82% to $107.6 million in 2024, then rose by 22.77% to $140.8 million in 2025.
  • Its Share-based Compensation was $140.8 million in Q3 2025, compared to $150.8 million in Q2 2025 and $95.5 million in Q1 2025.